Vinpocetine is the Forthcoming Adjuvant Agent in the Management of COVID-19

Al-Kuraishy, Hayder M; Al-Gareeb, Ali I; Fageyinbo, Muyiwa Samuel; Batiha, Gaber El‐Saber

doi:10.2144/fsoa-2021-0099

Cited by 25 publications

(22 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In its clinical perspective, IVN might be a pioneer drug in attenuating cardiotoxicity, mainly in patients with heart failure, arrhythmias, and malignancies treated by DXR. It has been shown that unlike β-blockers, IVN does not decrease ventricular force (Su et al 2020 ; Al-Kuraishy et al 2021b , 2022c , d ; Lawal et al 2021 ) and can also reduce COVID-19-induced cardiovascular complications due to its anti-inflammatory and antioxidant properties (Al-Kuraishy et al 2021c , 2022e ; Batiha et al 2021 , 2022 ). In addition, IVN facilitates a pleiotropic cardioprotective effect against isoproterenol-induced acute cardiac injury by increasing the ventricular fibrillation threshold (Simko et al 2021 ).…”

Section: Discussionmentioning

confidence: 99%

The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument

et al. 2022

Self Cite

View full text Add to dashboard Cite

This study investigated the potential role of ivabradine (IVN) in the attenuation of doxorubicin (DXR)-induced cardiotoxicity in rats. A total of 28 Swiss-Albino male mice were used, divided into four equal groups: the negative control did not receive any agents ( n = 7), the DXR group received a single dose of DXR 20 mg/kg ( n = 7), the treated group A was pretreated with IVN 5 mg/kg plus DXR ( n = 7), and the treated group B was pretreated with IVN 10 mg/kg plus DXR ( n = 7). The duration of this study was 10 days. Inflammatory biomarkers, including tumor necrosis factor alpha (TNF-α), lactate dehydrogenase (LDH), malondialdehyde (MDA), and cardiac troponin (cTn-I) serum levels were measured. TNF-α, LDH, MDA, and cTn-I serum levels were higher in the DXR-treated mice compared with the control ( P ˂0.01). IVN produced a dose-dependent effect in the reduction of MDA and cTn-I compared to DXR-treated mice ( P ˂0.05). Our findings suggest that IVN is an effective agent in mitigating DXR-induced cardiotoxicity due to its anti-inflammatory and antioxidant effects. IVN illustrated a dose-dependent effect in the attenuation of DXR-induced cardiotoxicity through inhibition of lipid peroxidation and cardiomyocyte injury.

show abstract

Section: Discussionmentioning

confidence: 99%

The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…In contrast, Hasanagic and Serdarevic proposed that α7nAchR antagonists such as memantine could be effective in the prevention and treatment of SARS-CoV-2 infection by inhibiting ACE2 expression in the respiratory epithelium (Hasanagic and Serdarevic 2020 ). Insufficiency of cholinergic neurotransmission is linked with the development of delirium and cognitive dysfunction in COVID-19 patients (Hshieh et al 2008 ; Al-Kuraishy et al 2022h ). In this state, CTN treatment may improve cholinergic neurotransmission by increasing the anti-inflammatory effect of Ach through α7nAchR-dependent effect.…”

Section: Citicoline and Cholinergic Neurotransmissionmentioning

confidence: 99%

Citicoline and COVID-19: vis-à-vis conjectured

Al-Kuraishy

Al-Buhadily

Al-Gareeb

et al. 2022

Naunyn-Schmiedeberg's Arch Pharmacol

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) is a current pandemic disease caused by a novel severe acute respiratory syndrome coronavirus virus respiratory type 2 (SARS-CoV-2). SARS-CoV-2 infection is linked with various neurological manifestations due to cytokine-induced disruption of the blood brain barrier (BBB), neuroinflammation, and peripheral neuronal injury, or due to direct SARS-CoV-2 neurotropism. Of note, many repurposed agents were included in different therapeutic protocols in the management of COVID-19. These agents did not produce an effective therapeutic eradication of SARS-CoV-2, and continuing searching for novel anti-SARS-CoV-2 agents is a type of challenge nowadays. Therefore, this study aimed to review the potential anti-inflammatory and antioxidant effects of citicoline in the management of COVID-19.

show abstract

“…Moreover, pregnancy and fetal delivery did not worsen the clinical outcomes and lung radiological imaging findings of COVID-19. In addition, most pregnant women with COVID-19 presented with mild symptoms and did not require antiviral therapy [ 24 , 101 ].…”

Section: Pregnancy and Covid-19mentioning

confidence: 99%

Pregnancy and COVID-19: high or low risk of vertical transmission

et al. 2022

Self Cite

View full text Add to dashboard Cite

Coronavirus disease 19 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome 2 (SARS-CoV-2). Throughout the pandemic, evidence on the effects of COVID-19 during pregnancy has been inadequate due to the limited number of studies published. Therefore, the objective of this systematic review was to evaluate current literature regarding the effects of COVID-19 during pregnancy and establish pregnancy outcomes and vertical and perinatal transmission during pregnancy. Multiple databases were searched, including Embase, Medline, Web of Science, Scopus, and Cochrane Central Register of Control Clinical Trials, using the following keywords: [Pregnancy] AND [COVID-19 OR SARS-CoV-2 OR nCoV-19] OR [Perinatal transmission, Vertical transmission (VT), Pregnancy complications], [Pregnancy] AND [Hyperinflammation OR Cytokine storm]. We excluded in vitro and experimental studies, but also ex-vivo and animal study methods. To exclude the risk of bias during data collection and interpretation, all included studies were peer-reviewed publications. This review is estimated to tabulate the study intervention characteristics and compare them against the planned groups for each synthesis. Our findings showed that pregnant women are commonly susceptible to respiratory viral infections and severe pneumonia due to physiological immune suppression and pregnancy-induced changes. VT of SARS-CoV-2 infection during pregnancy is associated with a great deal of controversy and conflict. However, there is still no robust clinical evidence of VT. Furthermore, the clinical presentation and management of COVID-19 during pregnancy are nearly identical to those of non-pregnant women. Finally, chloroquine and remdesivir are the only two drugs evaluated as adequate for the management of COVID-19 during pregnancy.

show abstract

Vinpocetine is the Forthcoming Adjuvant Agent in the Management of COVID-19

Cited by 25 publications

References 48 publications

The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument

The role of ivabradine in doxorubicin-induced cardiotoxicity: exploring of underlying argument

Citicoline and COVID-19: vis-à-vis conjectured

Pregnancy and COVID-19: high or low risk of vertical transmission

Contact Info

Product

Resources

About